Table 2. Features of rheumatoid arthritis patients that continued or stopped etanercept within first year of therapy.

	Continuing etanercept (n=407)				Stopping etanercept (n=70)
	n	%	Median	IQR	n	%	Median	IQR	p
Age (years)			53	17			51	15	NS
Disease duration (years)			5.4	8.2			5.6	8	NS
Body mass index			24.5	5.8			25.4	6.3	NS
Erythrocyte sedimentation rate			28	23,2			28	35	NS
Tender joints 28			9	11			8	16	NS
Swollen joints 28			5	9			5	9	NS
Disease activity score in 28-joint			5.5	1.7			5.9	2.1	NS
Mean dosage of MTX (mg/week)			15	5			10	5	NS
Gender
Female	323	79,4			59	84.3			NS
Current smoker	98	24,2			15	21.8			NS
Rheumatoid factor positive	268	65,8			47	67.1			NS
ACPA positive	249	61,2			48	68.6			NS
ACPA-RF positive	219	53,8			38	54.3			NS
RF positive alone	49	12			9	12.9			NS
ACPA-positive alone	30	7,4			10	14.3			NS
None	109	26,8			13	18.6			NS
Co-morbidities	64	15,7			20	28.6			0.009
Cardiovascular diseases	38	9,3			8	11.4			NS
Extra-articular manifestations	23	5,7			7	10			NS
Steroid therapy	210	51,6			40	57.1			NS
Etanercept monotherapy	194	47,7			24	34.3			0.038
DMARDs
Methotrexate	164	40,3			29	41.4			NS
Other DMARDs	49	12			17	24.3			0.006
C-Reactive protein (>5 mg/L)	277	68			46	65.7			NS
IQR: Interquartile range; MTX: Methotrexate; ACPA: Anti-citrullinated peptide antibody; RF: Rheumatoid factor; DMARD: Disease-modifying antirheumatic drug; NS: Not significant.